Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of carbohydrate restriction on postprandial glucose metabolism, β-cell function, gut hormone secretion, and satiety in patients with Type 2 diabetes.
Skytte MJ, Samkani A, Astrup A, Frystyk J, Rehfeld JF, Holst JJ, Madsbad S, Burling K, Fenger M, Thomsen MN, Larsen TM, Krarup T, Haugaard SB. Skytte MJ, et al. Among authors: samkani a. Am J Physiol Endocrinol Metab. 2021 Jan 1;320(1):E7-E18. doi: 10.1152/ajpendo.00165.2020. Epub 2020 Oct 26. Am J Physiol Endocrinol Metab. 2021. PMID: 33103448 Free article.
Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Anholm C, Kumarathurai P, Samkani A, Pedersen LR, Boston RC, Nielsen OW, Kristiansen OP, Fenger M, Madsbad S, Sajadieh A, Haugaard SB. Anholm C, et al. Among authors: samkani a. Diabetes Obes Metab. 2019 Aug;21(8):2012-2016. doi: 10.1111/dom.13761. Epub 2019 May 29. Diabetes Obes Metab. 2019. PMID: 31050161 Clinical Trial.
Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Anholm C, Kumarathurai P, Pedersen LR, Samkani A, Walzem RL, Nielsen OW, Kristiansen OP, Fenger M, Madsbad S, Sajadieh A, Haugaard SB. Anholm C, et al. Among authors: samkani a. Atherosclerosis. 2019 Sep;288:60-66. doi: 10.1016/j.atherosclerosis.2019.07.007. Epub 2019 Jul 5. Atherosclerosis. 2019. PMID: 31326727 Clinical Trial.
A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial.
Skytte MJ, Samkani A, Petersen AD, Thomsen MN, Astrup A, Chabanova E, Frystyk J, Holst JJ, Thomsen HS, Madsbad S, Larsen TM, Haugaard SB, Krarup T. Skytte MJ, et al. Among authors: samkani a. Diabetologia. 2019 Nov;62(11):2066-2078. doi: 10.1007/s00125-019-4956-4. Epub 2019 Jul 23. Diabetologia. 2019. PMID: 31338545 Clinical Trial.
Effects of a highly controlled carbohydrate-reduced high-protein diet on markers of oxidatively generated nucleic acid modifications and inflammation in weight stable participants with type 2 diabetes; a randomized controlled trial.
Skytte MJ, Samkani A, Astrup A, Larsen TM, Frystyk J, Poulsen HE, Henriksen T, Holst JJ, Andersen O, Madsbad S, Haugaard SB, Krarup T, Larsen EL. Skytte MJ, et al. Among authors: samkani a. Scand J Clin Lab Invest. 2020 Sep;80(5):401-407. doi: 10.1080/00365513.2020.1759137. Epub 2020 May 6. Scand J Clin Lab Invest. 2020. PMID: 32374188 Clinical Trial.
The clinical effects of a carbohydrate-reduced high-protein diet on glycaemic variability in metformin-treated patients with type 2 diabetes mellitus: A randomised controlled study.
Thomsen MN, Skytte MJ, Astrup A, Deacon CF, Holst JJ, Madsbad S, Krarup T, Haugaard SB, Samkani A. Thomsen MN, et al. Among authors: samkani a. Clin Nutr ESPEN. 2020 Oct;39:46-52. doi: 10.1016/j.clnesp.2020.07.002. Epub 2020 Aug 1. Clin Nutr ESPEN. 2020. PMID: 32859328 Clinical Trial.
19 results